Loading the session
Loading the session
Loading instrument
$1.64
−4.65%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:27 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +21.2% (SPY −1.6%, XLV +13.5%). 3 months: +31.1% (SPY −0.4%, XLV +15.5%). 1 year: +27.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: OPK, SPY and XLV · as of 4 Nov 2026
Closed at $1.77 on 4 Nov 2026: 2.2% below the 52-week high of $1.81 (3 Nov 2026) and 81.2% above the low of $0.98 (29 Apr 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
34.0M shares were sold short at the 15 Oct 2026 settlement, 4.6% of the 746.3M shares outstanding; covering them would take 5.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $1.77 was 12.1% above its 50-day average ($1.58) and 31.1% above its 200-day average ($1.35). It has closed above the 200-day for 16 sessions, since 14 Oct 2026. The 50-day average crossed above the 200-day on 6 Jul 2026, 86 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
July 28, 2026
+33.06%January 4, 2024
−39.55%January 24, 2022
−23.82%